Iobenguane I-131 - Progenics Pharmaceuticals

Drug Profile

Iobenguane I-131 - Progenics Pharmaceuticals

Alternative Names: 131-I-metaiodobenzylguanidine; 131-I-MIGB; 131I-iobenguane - Progenics Pharmaceuticals; 131I-MIBG - Progenics Pharmaceuticals; 3-iodobenzylguanidine-I-123; Azedra; HSA I-131 MIBG; I-131 mIBG; I-131-iobenguane; Iobenguane-I123-injection; Iobenguane-I131; Iobenguane-sulfate; Iodine-123 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131 iobenguane - Progenics Pharmaceuticals; Iodine-131 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131-metaiodobenzylguanidine; Iodine-I-131-metaiodobenzylguanidine; m-Iodobenzylguanidine-sulfate; Meta-iodobenzylguanidine; Metaiodobenzylguanidine-I-123; Metaiodobenzylguanidine-I-131; Metaiodobenzylguanidine-sulfate; MIBG; MIP-120T; Ultratrace I-131-MIBG; Ultratrace iobenguane I 131; Ultratrace MIBG; Ultratrace-iobenguane-I-131

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Molecular Insight Pharmaceuticals; Progenics Pharmaceuticals
  • Class Antineoplastics; Guanidines; Iodobenzenes; Radiopharmaceuticals; Small molecules; Sulfates
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Neuroendocrine tumours
  • Phase II Neuroblastoma

Most Recent Events

  • 04 Jun 2018 Additional efficacy data from a phase II trial in Neuroendocrine tumours released by Progenics Pharmaceuticals
  • 01 Jun 2018 Updated adverse events and efficacy data from a phase IIb trial in Neuroendocrine tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 22 Mar 2018 FDA extends PDUFA action date to 30/07/2018 for iobenguane I-131 for Neuroendocrine tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top